Human semaphorin L (H-SemaL) and corresponding semaphorins in other species

US7339030B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Bernhard Fleckenstein · Wiesenthau, DE
• Armin Ensser · Koblenzer Straße, DE

Key dates

• Filing date: Sep 3, 2004
• Grant date: Mar 4, 2008
• Expiry date: Sep 30, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel semaphorins which are distinguished by a particular domain structure and derivatives thereof, nucleic acids (DNA, RNA, cDNA) which code for these semaphorins, and derivatives thereof, and the use thereof.The present invention relates to semaphorins which have a novel, as yet undisclosed and unexpected domain structure and which possess a biochemical function in the immune system (immunomodulating semaphorins). The novel semaphorins are referred to as type L semaphorins (SemaL). They comprise an N-terminal signal peptide, a characteristic Sema domain and, in the C-terminal region of the protein, an immunoglobulin-like domain and a hydrophobic domain which represents a potential transmembrane domain.